Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized, double-blind, double-dummy trial

Clinical Infectious Diseases

Volumn 47, Issue 10, 2008, Pages 1270-1276

  Hamza, Omar J M ^a   Matee, Mecky I N ^a   Brüggemann, Roger J M ^b   Moshi, Mainen J ^a   Simon, Elison N M ^a   Mugusi, Ferdinand ^a   Mikx, Frans H M ^b   Van Der Lee, Henrich A L ^b   Verweij, Paul E ^b   Van Der Ven, André J A M ^b  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NAUSEA; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; DOUBLE-BLIND METHOD; FEMALE; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OROPHARYNX; PLACEBOS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 54249128253     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592578     Document Type: Article

References (29)

1. Matee MI, Scheutz F, Moshy J. Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. Oral Dis 2000; 6:106-11.
2. Kamiru NH, Naidoo S. Oral HIV lesions and oral health behaviour of HIV-positive patients attending the Queen Elizabeth II Hospital, Maseru, Lesotho. SADJ 2002; 57:479-82.
3. Ceballos-Salobreña A, Gaitán-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS 2000; 14:627-35.
4. Tappuni AR, Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:623-8.
5. Wood R. Management of HIV and AIDS in the African context. Oral Dis 2002; 8:32-3.
6. Hamza OJM, Matee MIN, Simon ENM, et al. Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health 2006; 6:12.
7. Campo J, Del Romero J, Castilla J, Garcia S, Rodriguez C, Bascones A. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med 2002; 31:5-10.
8. Ministry of Health, the United Republic of Tanzania, NACP: national guidelines for clinical management of HIV/AIDS 2005; 2:66-75.
9. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J Acquir Immune Defic Syndr 1993; 6:1311-6.
10. Pons VD, Greenspan F, Lozada-Nur L, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24:1204-7.
11. Phillips P, De Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26:1368-73.
12. Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:170-9.
13. Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104:33-9.
14. Baccaglini L, Atkinson JC, Patton LL, et al. Management of oral lesions in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(Suppl 50):e1-23.
15. De Wit S, Goossens H, Clumeck N. Single-dose versus 7 days of fluconazole treatment for oral candidiasis in human immunodeficiency virus-infected patients: a prospective, randomized pilot study. J Infect Dis 1993; 168:1332-3.
16. Chave JP, Cajot A, Bille J, Glauser MP. Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: a pilot study. J Infect Dis 1989; 159:806-7.
17. De Wit S, O'Doherty E, De Vroey C, Clumeck N. Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis. J Int Med Res 1998; 26:159-70.
18. Krammer IR, Pindborg JJ, Bezrouukov V, et al. Guide to epidemiology and diagnosis of oral mucosal diseases and conditions. World Health Organization. Community Dent Oral Epidemiol 1980; 8:1-16.
19. Silverman J, Migliorati J, Epstein L, Samaranayake LP. Laboratory diagnosis of oral candidosis. In: Samaranayake LP, MacFarlane TW, eds. Oral candidosis. London: Butterworth, 1990:213-37.
20. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard 2nd edition, M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
21. Ship JA, Vissink A, Challacombe SJ. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103:1-14.
22. Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. BMC Infect Dis 2005; 5:67.
23. de Maat MMR, ter Heine R, van Gorp ECM, Mulder JW, Mairuhu ATA, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003; 17:2209-14.
24. Littera R, Carcassi C, Masala A, et al. LA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20:1621-6.
25. Rodríguez-Tudela JL, Martínez-Suárez JV, Dronda F, et al. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J Antimicrob Chemother 1995; 35:793-804.
26. Querada C, Polanco AM, Giner C, et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996; 15:30-7.
27. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24:235-47.
28. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007; 51:3599-604.
29. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13:77-82.